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Abstract. The concept of repairing the brain with growth factors has been pursued for many years in a variety of neurodegen-
erative diseases including primarily Parkinson’s disease (PD) using glial cell line-derived neurotrophic factor (GDNF). This
neurotrophic factor was discovered in 1993 and shown to have selective effects on promoting survival and regeneration of
certain populations of neurons including the dopaminergic nigrostriatal pathway. These observations led to a series of clinical
trials in PD patients including using infusions or gene delivery of GDNF or the related growth factor, neurturin (NRTN).
Initial studies, some of which were open label, suggested that this approach could be of value in PD when the agent was
injected into the putamen rather than the cerebral ventricles. In subsequent double-blind, placebo-controlled trials, the most
recent reporting in 2019, treatment with GDNF did not achieve its primary end point. As a result, there has been uncertainty
as to whether GDNF (and by extrapolation, related GDNF family neurotrophic factors) has merit in the future treatment of
PD. To critically appraise the existing work and its future, a special workshop was held to discuss and debate this issue. This
paper is a summary of that meeting with recommendations on whether there is a future for this therapeutic approach and also
what any future PD trial involving GDNF and other GDNF family neurotrophic factors should consider in its design.
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INTRODUCTION34
The discovery and characterisation of specific35
neurotrophic factors in the context of neuronal devel-36
opment and synapseformation in the last half of37
the 20th century, led to the hypothesis that certain38
adult neuronal populations lost to chronic disease39
processes might be rescued and potentially regener-40
atedby the administration of these agents [1]. This41
has been extensively explored in Parkinson’s disease42
(PD) with the use of GDNF and related factor NRTN43
and the dopaminergic (DA) nigrostriatal pathway- the44
loss of which is known to be central and critical to the45
development and clinical expression of this condition46
[2].47
In this short paper, we critically appraise the48
pre-clinical and clinical trial work with GDNF and49
NRTN in patients with PD. This appraisal is based50
on a meeting held over 2 days in August 201951
that brought together experts who had direct and52
practical experience in this field. The timing of53
this meeting was linked to the recent publication a54
UK-based clinical trial and parallel airing on the55
BBC of the two-part documentary “The Parkin- 56
son’s Drug Trial: A Miracle Cure? [https://www. 57
bbc.co.uk/mediacentre/proginfo/2019/09/parkinsons 58
-drug-trial-a-miracle-cure]? The meeting was organ- 59
ised and funded by The Cure Parkinson’s Trust and 60
supported by The Michael J Fox Foundation and Van 61
Andel Institute. 62
THE PRECLINICAL EVIDENCE THAT 63
GDNF CAN RESCUE THE 64
NIGROSTRIATAL PATHWAY 65
The discovery of GDNF in 1993 was made at a 66
time of great interest in the therapeutic development 67
of neurotrophic factors which offered potential for 68
treating a number of disease states. The search for a 69
survival factor with high selectivity for midbrain DA 70
neurons had already been going on for some time. 71
As such, when Lin et al. reported the cloning and 72
bioactivity of this new trophic factor in 1993 there 73
was great excitement [3]. Indeed, this in part helps 74
explain why there was such a short time span between 75
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the first pre-clinical in vivo studies (performed and76
published in 1994-95) and the first clinical trial with77
this agent [4] which started recruiting patients in July78
1996.79
The second member of the GDNF family of lig-80
ands, NRTN, was discovered in 1996 [5] along with81
the receptor signaling pathways for these 2 factors82
[6]. This work revealed that while GDNF and NRTN83
are members of the transforming growth factor beta84
(TGF-) family, they signal through a completely85
different receptor system compared to other TGF-86
family members. GDNF first binds to the Glyco-87
sylphosphatidylinositol (GPI)-anchored co-receptor88
GDNF family receptor alpha-1 (GFR1) and then89
the GDNF-GFR1 complex binds to, and activates90
the transmembrane receptor tyrosine kinase RET.91
NRTN likewise signals to the cells via the RET92
receptor, but its binding to RET is mediated through93
the GFR2 co-receptor although when delivered at94
high levels it also can bind to GFR1[6].RET then95
activates the intracellular mitogen-activated protein96
kinase (MAPK), Akt (protein kinase B) and Src sig-97
naling cascades that are responsible for the survival98
and regeneration of DA neurons. It is important to99
stress that GDNF and NRTN trigger rapid responses100
in DA neurons through protein phosphorylation, but101
in addition to that they activate a number of tran-102
scription factors that have longer-lasting effects on103
DA neurons104
The initial work with GDNF was made possi-105
ble through having access to a recombinant human106
form of protein from Synergen and Genentech. This107
enabled the generation of preliminary in vivo data108
on DA neuroprotection in the three rodent PD mod-109
els available at the time: the rat 6 hydroxydopamine110
(6-OHDA) model [7, 8], the mouse 1-methyl-111
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model112
[9] and the knife-transection model [10]. In addi-113
tion, a study performed in intact rats showed that114
GDNF, administered into the substantia nigra, could115
stimulate DA neuronal function [11]. The fact that116
the findings from all of these studies provided posi-117
tive evidence in the same direction was re-assuring –118
namely a growth factor that seemed to work on DA119
neuronal rescue and regeneration.120
These initial preclinical studies used intracere-121
bral administration of GDNF, (single or repeated122
injections of microgram amounts over the substan-123
tia nigra). Nevertheless, Amgen, the company that124
had acquired the rights to GDNF, opted for an125
intraventricular delivery approach in its first clin-126
ical trial [4] (see below). A critical factor in this127
decision were the results of a study, sponsored by 128
Amgen, reporting significant, dose-dependent ben- 129
eficial effects obtained by monthly intraventricular 130
injections of GDNF in MPTP-treated rhesus mon- 131
keys [12]. The results again looked promising: all the 132
major motor features (bradykinesia, rigidity, posture 133
and balance) were improved when assessed 4 weeks 134
after the last (fourth) monthly injection. Doubts on 135
this mode of administration, however, soon arose: 136
studies on the distribution of GDNF after intraven- 137
tricular delivery indicated very limited diffusion into 138
the brain parenchyma given its strong binding to 139
extracellular matrix and cell surface heparin sulphate 140
proteoglycans [13, 14]. Furthermore, a follow-up 141
study by another team, performed in the same mon- 142
key model, failed to show any protective effect on the 143
MPTP-lesioned DA neurons [15]. 144
While this trial was ongoing, experimental work 145
performed in rodent and primate PD models pro- 146
vided further and more compelling evidence that 147
GDNF must be administered directly into the brain 148
parenchyma to exert its actions, and that the site, dose 149
and timing of GDNF delivery are important. Experi- 150
ments in 6-OHDA lesioned rats showed that delivery 151
into the substantia nigra could rescue DA neuronal 152
cell bodies against toxic damage but failed to protect 153
their axonal projections in the striatum [16]. Res- 154
cue of both DA neuronal cell bodies and their axons 155
projecting to the striatum required that the factor be 156
delivered into the striatum, or into both the striatum 157
and substantia nigra, provided that it is given before 158
or soon after the toxin treatment [17]. Furthermore, 159
the timing of the delivery of GDNF was also found 160
to be important. In both rodents and primates there 161
was evidence that delayed intrastriatal GDNF deliv- 162
ery, starting weeks or months after 6-OHDA or MPTP 163
treatment, couldstill protect surviving DA neurons 164
and stimulate regenerative sprouting from spared 165
axons in the partially denervated striatum [18–21]. 166
Based on all this experimental data it was con- 167
cluded that the therapeutic potential of GDNF is 168
due to a combination of three interacting mecha- 169
nisms: 1) Protection of midbrain DA neurons against 170
toxin-induced cell death; 2) stimulation of axonal 171
regeneration in the area reached by GDNF; and 3) 172
recovery of function through up regulation of DA 173
turnover and release. 174
These experimental studies, performed over the 175
first decade after GDNF’s discovery, were very 176
encouraging and stimulated a series of clinical trials, 177
including some where the agent was given intra- 178
putaminally (see below). At that time, the preclinical 179
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data seemed to support such a move to the clinic180
based on all the studies performed in mice, rats and181
non-human primates. There were, however, obvious182
weaknesses in the pre-clinical data: Firstly, GDNF183
was relatively ineffective in the face of severe lesions184
giving >80% loss of DA neurons which more closely185
mimics the human condition. Secondly, the data186
showing efficacy was obtained in toxin-based models187
where 6-OHDA or MPTP are administered acutely188
which results in a degenerative process that is pri-189
marily driven by oxidative damage or mitochondrial190
dysfunction not protein aggregation. Further, these191
models do not replicate the late stages of PD nor192
the progressive, alpha-synuclein related pathophys-193
iology that is characteristic of the human disease.194
Given this difference, there was a concern that the195
results obtained in toxin-based models may not be196
predictive for human PD patients receiving this exper-197
imental therapy. In addition, there were also concerns198
about whether the GDNF made at that time using E.199
coli (as opposed to human recombinant protein made200
in mammalian cells) would work less well in human201
patients.202
Some of these anxieties have been borne out in203
more recent experiments. Over the last few years204
the access to alpha-synuclein-based PD models has205
allowed this first question to be further explored [22].206
These models not only offer better opportunities to207
more faithfully replicate the alpha-synuclein related208
pathology seen in people with PD, but the lesions so209
induced evolve slowly over time in contrast to the210
far more rapid time course of acute toxin models of211
PD. Using such alpha-synucleinopathy models, stud-212
ies designed to reproduce the type of neuroprotective213
and restorative effects of GDNF, consistently seen in214
MPTP and 6-OHDA models, have so far failed [23,215
24].216
In a follow-up study performed in the AAV-217
alpha-synuclein model [25], Decressac et al. (2012)218
suggested that this could be due to a failure of alpha-219
synuclein overexpressing nigral neurons to respond220
to GDNF. This, the authors postulated, could be221
due to down regulation of the GDNF receptor RET,222
mediated by a reduced expression of the DA related223
transcription factor, nuclear receptor related 1 protein224
(Nurr1). Nurr1 is known to regulate RET expres-225
sion in DA neurons [26] and the two are thus closely226
related.227
In human PD postmortem material, Nurr1 has been228
shown to be down-regulated in DA neurons that229
over express alpha-synuclein [27] and a similar down230
regulation of Nurr1 is also seen in alpha-synuclein231
over expressing neurons in the AAV model of PD. 232
This, in turn, is accompanied by a marked reduc- 233
tion in the expression of RET [25]. The dependence 234
on Nurr1/RET expression is further supported by an 235
experiment performed in Nurr1 deleted mice show- 236
ing that the ability to respond to GDNF is abolished 237
in DA neurons lacking Nurr1 [25]. 238
The findings obtained in the AAV-alpha-synuclein 239
model should however be interpreted with caution. 240
The cellular levels of alpha-synuclein obtained in this 241
model are artificially high (4-5-fold above normal) 242
and thus may not reflect the milieu in the affected DA 243
neurons in the PD brain. Furthermore, showing that 244
RET expression is reduced in the human PD brain 245
has proven inconclusive (see Su et al. 2017 for a 246
dissenting view [28]). 247
In summary, the preclinical data suggests that 248
GDNF can rescue DA neurons and their projections 249
in the nigrostriatal pathway in a range of toxin animal 250
models butthe ability to rescue may be different in the 251
context of the alpha synuclein pathology that is seen 252
in the brain of people with PD. 253
THE EARLY CLINICAL TRIALS 254
The move from the lab to the clinic is always chal- 255
lenging and in order to assess progress and success, 256
new agents are often evaluated against four key ele- 257
ments. These include whether the drug (in this case 258
GDNF for PD): 259
• Reaches its proposed site of action at sufficient 260
concentrations (namely the DA nigrostriatal 261
pathway); 262
• Shows target engagement at that sitein a mea- 263
surable way (GFRa1/RET signalling leading to 264
positive changes in this DA system); 265
• Displays functional downstream pharmacolog- 266
ical effects(shows sprouting, growth and /or 267
survival of DA fibres/synapses in the presence 268
of an ongoing degenerative disease process); 269
• Exhibits improvement in the relevant phenotype 270
of the treated individuals (better motor perfor- 271
mance around measures known to be sensitive 272
to this DA network). 273
The first of these criteria falls under the umbrella of 274
delivery, the latter three provide a basis for potential 275
efficacy, if delivery sufficient to cover the putamen 276
can be achieved. In the sections below, we consider 277
the open-label and double-blind, placebo-controlled 278
clinical trials to-date in which recombinant human 279
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GDNF has been directly administered to people with280
PD. This will be followed by a description and dis-281
cussion of the clinical studies where a related trophic282
factor NRTN was administered as a viral vector injec-283
tion to the basal ganglia as well as an ongoing GDNF284
gene therapy trial.285
The initial double-blind randomised control trial286
of intracerebroventricular Injections of GDNF287
protein288
The first clinical trial of GDNF was conducted289
by Amgen and was a multicentre, randomized,290
double-blind, placebo-controlled study of intracere-291
broventricular (ICV) administration of GDNF [4].292
Monthly ICV injections were given via an intraven-293
tricular cannula inserted in the right frontal horn using294
standard stereotactic techniques. This was a dose295
escalation study with five dosage arms (25g, 75g,296
150g, 300g, and 4000g) with 7-8 patients297
receiving active drug and 2-3 patients receiving298
placebo for a period of 8 months followed by an299
open-label extension period of up to an additional300
20 months giving maximum single doses of up301
to 4,000g in 16 subjects. The primary outcome302
variables, the change in “practically defined OFF”303
and ON motor Unified Parkinson’s Disease Rating304
Scale (UPDRS) scores, were not significantly dif-305
ferent from placebo in any of the active treatment306
groups apart from a mild but significant worsening307
in OFF scores in the 75g group and ON scores in308
the 300g group. Adverse effects were more com-309
mon in the active treatment groups and included310
anorexia, weight loss (>5% body weight), hypona-311
tremia and the unexpected finding (at the time) of312
sensory symptoms such as paraesthesia and Lher-313
mitte’s phenomenon.314
Although the adverse effect profile indicated that315
GDNF administered by ICV injection was having316
biological effects (the anorexia and weight loss were317
thought to be due to its action in the hypothalamus),318
this approach did not improve the clinical state of the319
patient.320
It was postulated that this lack of benefit could321
relate to a failure of GDNF to reach and mediate322
effects in the target tissue (putamen and indirectly323
the substantia nigra) [4]. Supporting this hypothe-324
sis was a report of the postmortem assessment of325
a single patient from this trial [29]. In contrast to326
experiments in monkeys, where GDNF immunore327
activity was observed within the caudate nucleus ipsi-328
lateral to the infused ventricular frontal-horn and in329
the septum bilaterally (although whether this was suf- 330
ficient to activate RET signalling was not assessed), 331
the human postmortem evaluation demonstrated no 332
intra-parenchymal diffusion of GDNF across the 333
cerebrospinal fluid: brain barrier from the ventric- 334
ular cavity to the relevant basal ganglia structures. 335
As such, it was to be expected that the autopsied 336
tissue failed to demonstrate evidence of significant 337
regeneration of nigral neurons and their fibres [29]. 338
While this first in-human trial failed to hit its 339
primary end point, the above results showed that 340
monthly infusions of a biologic-agent unable to pen- 341
etrate the blood-brain-barrier was well tolerated and 342
“relatively” safe even when high doses of GDNF were 343
given (4000g) [4]. However, the lack of parenchy- 344
mal penetration coupled with an absence of motor 345
benefitled on to further trials with infusions directly 346
to the putamen. 347
The initial open label trials of intraputaminal 348
Injections of GDNF protein 349
To ensure that GDNF reached the DA termi- 350
nal plexus within the posterior-dorsal striatum, two 351
small open label studies evaluated direct-to-putamen 352
continuous (rather than bolus) catheter infusions 353
of GDNF [30, 31]. To effect continuous infusions, 354
GDNF was administered from subcutaneous pumps 355
placed in the abdomen connected to a single catheter 356
to each putamen in a5-patient cohort in Bristol, UK 357
and to a single-sided unilateral catheter only in a 10- 358
patient cohort studied in Kentucky, USA. The Bristol 359
group initially reported after 6 and 12 months as did 360
the Kentucky group [30, 31]. Doses in the Kentucky 361
study were escalated to 30g per day and in the 362
Bristol trial, patient’s doses were on average 30g 363
per day. Some patients did receive even higher doses 364
(>30g GDNF per day)but this produced high sig- 365
nal changes on MRI in the putamen—changes which 366
resolved with dose reduction. 367
Both of these small open label studies reported 368
marked benefits in UPDRS motor (part III) scores in 369
the practically defined OFF state with a mean reported 370
improvement of approximately 30%–40%. Changes 371
in diary fluctuations were equally encouraging at this 372
open-label stage [30, 31] although it should be noted 373
that the changes were bilateral even in patients who 374
had been in receipt of unilateral infusions for reasons 375
that were not clear. 376
In the Bristol study,18-fluorine- 377
dihydroxyphenylalanine ([18F]DOPA)positron 378
emission tomography (PET) scans showed an 379
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increase in tracer uptake mainly around the catheter380
tip, which potentially represented sprouting of381
remaining terminals, supported in part by a382
subsequent single case postmortem study [32].383
In the Kentucky study, there was one serious384
adverse event (SAE) when the catheter became385
exposed which was associated with oedema around386
the catheter track in the putamen of this same patient.387
Three patients reported mild tingling sensations in the388
forehead, neck and lower back and two patients expe-389
rienced transient Lhermitte’s phenomenon. Seven390
patients developed antibodies to GDNF without clini-391
cal sequelae. High resolution MRI scans revealed that392
there was no evidence of GDNF-induced cerebellar393
toxicity, which became more of a concern in some394
of the later preclinical non-human primate studies395
with GDNF (see below). Finally, all improvements in396
UPDRS scores were lost within 9-months of stopping397
the GDNF infusions.398
Based on these encouraging open label observa-399
tions, a prospective, double-blind, placebo-controlled400
trial of continuously infusing GDNF to the putamen401
was initiated.402
DOUBLE-BLIND,403
PLACEBO-CONTROLLED TRIALS404
The Amgen trial405
Amgen sponsored the first double-blind trial406
involving direct intra-putaminal delivery of407
GDNF. In this multicentre trial, patients were408
randomized 1 : 1 to receive bilateral continuous409
intra-putaminal infusions of either GDNF at a dose410
of 15g/putamen/day or placebo [33]. One catheter411
was stereotactically placed on each side with itstip412
targeted to the posterior-dorsal putamen and attached413
to a separate SynchroMed pump (Medtronic),414
implanted subcutaneously over the patient’s415
abdomen. The primary end point was the change416
in UPDRS motor score in the practically defined417
OFF condition at 6 months. Secondary end points418
included other UPDRS scores, motor tests, dyskine-419
sia ratings, patient diaries, and [18F]-DOPA uptake420
on positron emission tomography (PET) imaging.421
Patients were stratified by baseline UPDRS OFF422
motor score (<44, >45) and 30 subjects (15 in each423
group) were calculated to be needed to give a 90%424
power to detect a between group difference of 25%425
in the percent change in UPDRS OFF motor score.426
34 patients were implanted and randomized; 17427
received GDNF (all completed the trial), and 17428
received placebo (with 16 completing the trial, and429
one discontinuing due to pump site infection). At 6 430
months, the mean percentage change in OFF UPDRS 431
motor score was –10% in the GDNF group com- 432
pared to –4.3% in the placebo group which was not 433
statistically significant. Secondary end point results 434
were also similar between the groups. There was no 435
significant relationship between the change in motor 436
scores and the catheter tip location. In the two thirds 437
of paired evaluable PET scans (1/3 of paired scans 438
were excluded due to head movement artefact) there 439
was a 32.5% treatment difference favouring GDNF in 440
mean [18F]DOPA influx constant (p = 0.019) but this 441
did not correlate with changes in the OFF UPDRS 442
motor scores. Procedure- and device-related compli- 443
cations were not uncommon while treatment related 444
complications were infrequent. The marked anorexia 445
and weight loss observed in the higher dose ICV study 446
were not seen. Serious, device-related adverse events 447
required surgical repositioning of catheters in two 448
patients and removal of devices in another [33]. 449
Three patients, one in the double-blind phase and 450
two in the open label extension, developed neu- 451
tralizing anti-GDNF antibodies—again without any 452
obvious clinical sequelae- which may relate to the 453
way the GDNF was delivered with leakage to the 454
periphery, and activation of the immune system. 455
Furthermore, contemporaneously, new toxicologi- 456
cal studies in non-human primates (NHPs) found 457
focal limited loss of Purkinje cells and near com- 458
plete loss of molecular and granule cell layers in 459
3/5 monkeys rapidly withdrawn from 3 months of 460
unilateral infusions of much higher doses of GDNF 461
(100g/putamen/day) while one monkey continuing 462
on treatment was found to have milder cerebellar 463
cortical pathology [34]. 464
As a result of this combination of a negative clin- 465
ical double-blind placebo-controlled trial result, the 466
finding of neutralizing antibodies in a small number 467
of patients and concerns about the NHP toxicological 468
findings, Amgen chose to terminate their GDNF pro- 469
gram for PD. This led to a vigorous debate between 470
various researchers and patient groups as to why 471
the double-blind trial and the open-label studies had 472
come to different conclusions. These included: 473
1. The potential for a major placebo effect in open- 474
label trials given it involved an invasive surgical 475
approach and problems in maintaining true clin- 476
ical equipoise. However, it should be noted that 477
in the double-blind study there was no major 478
placebo effect, but rather an absence of a posi- 479
tive clinical effect in either group. 480
Un
co
rre
cte
d A
uth
or
 P
ro
of
R.A. Barker et al. / GDNF and Parkinson’s Disease 7
2. Differences in dosages given, in particular481
higher doses were generally used in the open482
label studies, although benefit had also been483
claimed with lower doses in these early studies;484
3. Differences in delivery including catheter485
dimension and design. In general, catheter486
dimensions including its external diameter,487
design (no step, stepped or recessed stepped)488
and number of catheters inserted along with489
implantation technique could all have an effect490
on the extent to which the agent was delivered491
and remained at the target site. In addition, dif-492
ferences in the diffusion of the agent across the493
target structure could also have impacted on494
the total volume of putaminal tissue exposed to495
study drug (see below) [35] and thus its poten-496
tial therapeutic effectiveness. All of this has led497
to the development of new convection enhanced498
delivery systems (see below).499
4. Differences in the patients selected for trials,500
in particular whether more advanced patients501
with more severe DA losses were recruited to502
the double-blind study.503
Given this uncertainty, there was a feeling in some504
quarters that this therapy should not be abandoned505
at this stage, a position reinforced by further obser-506
vations from the original open-label Bristol cohort507
[32, 36, 37]. This included the fact that the origi-508
nal five subjects who continued to receive continuous509
infusions from 12 to 24 months and beyond, all main-510
tained their improved UPDRS part II and part III511
OFF scores compared to baseline, consistent with512
their improved [18F]DOPA PET data [36]. Finally,513
one subject who had been infused continuously for 39514
months and then reviewed at 36 months after GDNF515
cessation, continued to experience a major clinical516
benefit. This benefit was accompanied by [18F]DOPA517
PET putaminal uptake that continued to show an518
improvement compared to pre-treatment scans [37].519
Although a single case, this did support the concept520
that GDNF might still work if methodological aspects521
of its administration were improved. Thus, a new522
GDNF trial was proposed.523
The recent Bristol study524
This new double-blind investigation of directly525
administered GDNF took the form of a randomised,526
placebo-controlled, single-centre trialsponsored by527
the UK National Health Service (and funded by528
Parkinson’s UK and The Cure Parkinson’s Trust)529
which started in 2012[38] (NCT03652363). Patients 530
selected were 35–75 years old, had motor symp- 531
toms for 5 or more years, with moderate disease 532
severity in the OFF state (Hoehn and Yahr stage 533
2–3 and a UPDRS motor score between 25–45) and 534
motor fluctuations (average of at least 2.5 hours of 535
OFF time per day on 3-day fluctuation diaries). They 536
all had marked levodopa responsiveness as defined 537
by a≥ 40% improvement in UPDRS motor score 538
following a levodopa challenge after a practically 539
defined OFF period. Importantly, the major differ- 540
ence with this trial with what had gone before was 541
the use of a new delivery device designed to establish 542
excellent coverage of the putamen. 543
Once implanted with this new intermittent 544
enhanced drug administration system that enabled 545
convection enhanced delivery (CED), patients were 546
randomised. Post-randomisation, patients received 547
a total of 10 study treatments at 4-weekly inter- 548
vals (Weeks 0 to 36). At each treatment, 400L 549
of infusate (300L GDNF or placebo, followed by 550
100L aCSF) was delivered per catheterinto the 551
post-commissural putamen at a GDNF concentra- 552
tion of 0.2g/L. Thus, the total GDNF dose given 553
every 4 weeks was 240g (120g/putamen given as 554
60g/catheter). 555
The results of this trial were published in February 556
2019 [38] and it revealed that the trial did not reach 557
itsprespecified primary endpoint; the mean OFF state 558
UPDRS motor score decreased by 17.3 ± 17.6% in 559
the active group and 11.8 ± 15.8% in the placebo 560
group.A range of secondary and supplementary 561
efficacy endpoints also failed to show significant dif- 562
ferences between the groups as well.In contrast to the 563
non-significant clinical results, the [18F]DOPA PET 564
findings were positive. Between baseline and Week 565
40 there was no change in the placebo group, whereas 566
in the GDNF group there were significant changes 567
across the putamen (in a graded fashion ranging from 568
25% anteriorly to 100% in the posterior putamen) but 569
not in the caudate (which acted as an internal control). 570
These marked relative percentage increases, while 571
statistically significant, still meant that the absolute 572
improvement was only toa level that was 50–60% 573
of that seen in the normalintact posterior putamen 574
which may explain why the treatment did not result 575
insignificant clinical changes. 576
At the conclusion of this double-blind study, all 577
patients had the chance to enrol into an open label 578
extension trial that used the same GDNF dose regi- 579
men and intermittent infusion parameters as for the 580
initial double-blind study. This open label exten- 581
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sion trial, also lasted 40 weeks, and was initiated582
before the results from the double-blind parent inves-583
tigation were known. It was undertaken primarilyto584
gain longer term safety data and to gather further585
exploratory information on GDNF clinical effects586
over a more prolonged period of repeated tissue expo-587
sures [39].588
The primary endpoint of this extension study589
was the percentage change from baseline (Week 0)590
to Week 80 in the practically defined OFF state591
UPDRS motor score, comparing the group that had592
received GDNF in the initial trial followed by open-593
label GDNF (GDNF/GDNF) versus the group that594
received placebo in the parent investigation followed595
by open-label GDNF (placebo/GDNF) (in effect a596
delayed-start design). Secondary endpoints included597
absolute change from baseline in OFF and ON state598
UPDRS part II and part III scores and change from599
baseline in diary ratings. A further pre-specified600
secondary endpoint included comparing Week 80601
UPDRS scores in the GDNF/GDNF group against602
Week 40 scores in the placebo/GDNF group (i.e., at603
the end of the placebo treatment).604
All 41 parent study participants were enrolled into605
the extension study, and all were included in the anal-606
yses. Again, there were no significant differences.607
Comparing baseline (Week 0) to the end of treat-608
ment (Week 80), the OFF state UPDRS motor score609
improved by 26.7 ± 20.7% (mean ± standard devia-610
tion) in the GDNF/GDNF group and by 27.6 ± 23.6%611
in the placebo/GDNF group. Likewise, none of the612
secondary or supplementary outcomes spanning the613
entire 80-week period were significantly different614
outside changes in L-DOPA equivalent dose (the615
increase in the daily L-DOPA equivalent dose from616
baseline to Week 80 was smaller in the GDNF/GDNF617
group (59 ± 194 mg) than in the placebo/GDNF618
group (289 ± 365 mg) [35].619
Treatment emergent adverse events (TEAEs,620
events commencing post initiation of GDNF or621
placebo infusions) were reported for all 41 patients.622
No patient had a TEAE that led to discontinuation of623
study medication. Of the eight serious TEAEs, three624
were considered to be device related and included625
two occurrences of a hypertrophic skin reaction626
around the port site that required surgical skin thin-627
ning and a possible port site infection that occurred628
approximately 15 weeks into the treatment phase and629
required inpatient treatment with oral antibiotics.630
Two patients enrolled into the double-blind study631
did not proceed to randomisation and were withdrawn632
prior to the start of treatment because they failed633
the post-surgery eligibility criteria. One patient expe- 634
rienced a mildly symptomatic putaminal ischemic 635
stroke coincident with the initial test infusion. The 636
patient recovered completely but was withdrawn to 637
avoid unnecessary risks. The second patient suffered 638
a small asymptomatic haemorrhage in both putamina 639
during the initial test infusion. 640
Blood sample analyses showed no measurable 641
GDNF plasma concentrations and no GDNF-binding 642
serum antibodies in GDNF-treated patients at any 643
point. This contrasts with the double-blind Amgen 644
study and the earlier open label studies and may 645
relate to the different delivery devices and delivery 646
regimens that were used in each trial. 647
In summary, these two studies have shown that 648
direct infusions of GDNF administered in a man- 649
ner to achieve CED can be given every 4-Weeks 650
over 18 months in a fashion that patients found 651
tolerable. Employing this approach, as evidenced 652
by a combination of direct Gadolinium infusion 653
through the delivery system and improvement in 654
[18F]DOPA PET uptake, appeared to achieve accu- 655
rate and whole putamen-wide target tissue delivery 656
with some evidence of target receptor engagement 657
using PET imaging. Despite this apparent optimisa- 658
tion of delivery, however, the clinical primary and 659
secondary endpoints in both trials were negative. 660
Whilst the partial restoration in PET signal may alle- 661
viate some of the concerns around insensitivity to 662
GDNF in the face of an alpha-synucleinopathy or that 663
patients more than 5 years from the point of diagno- 664
sis have no terminals left to restore, the fact remains 665
that improvement in [18F]DOPA PET signal cannot 666
be used as evidence for improvement in functional 667
pharmacology, especially as this tracer has also been 668
said to label inflammation [40]. Questions therefore 669
remain over whether the lack of significant benefit 670
in placebo-controlled trials to date reflects therapeu- 671
tic ineffectiveness or whether this would be resolved 672
with an increased dose and exposure of mammalian 673
cell made GDNF coupled totreating patients with ear- 674
lier stage disease. 675
GENE THERAPY TRIALS WITH NRTN 676
AND GDNF 677
In contrast to the immense logistical challenges 678
and potential safety concerns associated with contin- 679
uous or repeated long-term delivery of recombinant 680
GDNF protein, gene therapy promises sustained, 681
durable and localized production of properly folded 682
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biologically active GDNF following a one-time dos-683
ing procedure. Several clinical studies have now been684
conducted in PD, including a multi-phase program of685
NRTN gene transfer, a homolog of GDNF, and more686
recently a Phase 1 clinical safety trial of GDNF gene687
transfer. Both the NRTN and GDNF gene therapy688
programs utilized gene transfer vectors derived from689
the non-pathogenic adeno-associated virus serotype690
2 (AAV2) with a constitutive CMV promoter. These691
vectors appear to have a favourable safety profile for692
neurotrophic factor gene delivery in PD, in addition693
to which AAV2 has an exclusive neuronal tropism694
and restricted distribution when directly delivered to695
the brain [41], thus minimising off target side effects.696
The initial preclinical studies exploring this697
approach demonstrated that GDNF and NRTN698
gene delivery conveyed efficient protection against699
MPTP/6-OHDA lesions when the gene transfer was700
performed prior to, or shortly after, neurotoxin expo-701
sure. However, in an attempt to more closelymimic702
both early and later stages of PD a more refined MPTP703
model was developed innon-human primates (NHPs704
[21, 42]). Using this model, animals with established705
parkinsonian signs were randomized to receive either706
1) AAV2-GDNF (9.9 × 1011 vector genomes, vg;707
n = 8), or 2) sham PBS (n = 7) intraputaminal infu-708
sions via CED [21], and were followed for 1, 6, 14,709
or 24 months.710
In one of these NHP studies, it was demon-711
strated that there were marked functional motor712
improvements following AAV2-GDNF (mean 56%713
reduction of motor rating scores) in both the mod-714
erately and severely lesioned MPTP monkeys. This715
motor recovery directly correlated with increased 6-716
[18F]Fluoro-L-M-tyrosine (FMT) PET uptake that717
remained stable throughout the 24-month time point718
and which also correlated with enhanced dopamine719
and dopamine metabolites when assayed from tis-720
sue homogenates from these same animals. Increased721
tyrosine hydroxylase-immunore active (TH-IR) fibre722
density was also seen in the partially lesioned hemi-723
sphere (equivalent to “early” PD) receiving the724
AAV2-GDNFbut was much less prominent in the725
severely lesioned side (comparable to advanced PD).726
Together these findings suggested that intraputaminal727
infusions of AAV2-GDNF were safe and that greater728
parenchymal GDNF levels (∼24 ng/mg protein) were729
well-tolerated, without the adverse effects seen with730
protein infusions of GDNF (e.g., weight loss) [4,731
33]. This also indicates that GDNF is capable of732
restoring dopaminergic terminals with an associated733
significant recovery of motor function, particularly734
in the partially lesioned conditions. In addition, there 735
was strong evidence that GDNF delivery provided 736
greater potential for intrinsic TH-IR positive sprout- 737
ing in earlier rather than later stages of nigrostriatal 738
degeneration. 739
These and related studies [43] also found that 740
there was anterograde transport of AAV2-GDNF, via 741
direct and indirect connections, which was indepen- 742
dent of the degenerating nigrostriatal dopaminergic 743
(DA)neurons [43, 44] and their capacity to retro- 744
gradely transport GDNF protein. This mechanism 745
resulted in the broad expression of GDNF from the 746
putamen to the substantia nigra (SN) pars retic- 747
ulata, despite varying degrees of nigrostriatal DA 748
neuro degeneration and raised the potential that this 749
therapeutic may provide distinct advantages through 750
rebuilding DA nigrostriatal networks within the PD 751
brain. 752
This NRTN preclinical work led to clinical tri- 753
als that were performed by Ceregene Inc. using 754
the AAV-2 serotype and the NRTN transgene, the 755
first of which was an open label clinical trial [45] 756
(NCT00252850). Twelve patients aged 35–75 years 757
with a diagnosis of PD for at least 5 years, in 758
accordance with the Parkinson’s UK Brain Bank 759
Criteria, received bilateral, stereotactic, intraputami- 760
nal injections of AAV2-neurturin (CERE-120). The 761
first six patients received doses of 1.3 × 1011 vec- 762
tor genomes (vg)/patient, and the next six patients 763
received 5.4 × 1011 vg/patient. The treatment was 764
well tolerated with no side effects and a number of 765
clinical endpoints suggested improvement. However, 766
disappointingly there was no increase in 18F-DOPA 767
uptake on PET imaging. 768
This initial trial was followed by a multi-centre 769
randomized (2 : 1) double-blind trial comparing intra- 770
putaminal injections of AAV2-neurturin to sham 771
surgeryin 58 PD patients [46]. An infusion volume 772
of 40l of vector was injected into each putamen 773
with subjects in the active treatment arm receiving a 774
dose of 5.4 × 10¹¹ vg/patient. Disappointingly, there 775
was no significant difference between the two groups 776
based on UPDRS Part III motor scores in the OFF 777
state at 12 months post-transduction, the primary 778
endpoint. However, a significant placebo effect was 779
noted, with a 6-point reduction in UPDRS seen at 3 780
months in the sham group, which persisted for the 781
duration of the study. However, a pre-specified post- 782
hoc analysis suggested that those patients blindly 783
assessed at the 15–18 months post-treatment time 784
point may have had some benefit, although there was 785
no controlling for multiple comparisons. In addition, 786
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it should be noted that the whole cohort could not be787
followed blindly out to these time points due to the788
ending of the trial and the blind being broken at 12789
months. This may have created a bias in the effect790
seen.791
Histological data from patients who died from792
events unrelated to the procedure, indicated that793
NRTN was being expressed within the vicinity of the794
injection sites, and that this resulted in focal upreg-795
ulation of TH, but to an extent that was probably796
insufficient to provide any clinical benefit. Addition-797
ally, there was very limited NRTN seen in nigral798
neurons, suggesting that severity of the nigrostriatal799
axonopathy in these advanced PD patients did not800
allow sufficient retrograde transport of NRTN to the801
nigral perikarya to provide neurorestorative effects802
[47].803
Based on the small area of transduction, the lack804
of NRTN expression in nigral neurons, the perceived805
defect in retrograde transport and the potential for806
changes to occur at a longer time-point, a second ran-807
domized double-blind trial comparing higher putam-808
inal volumes plus a direct injection into the nigra809
was undertaken [48]. Fifty-one patients were enrolled810
in this multi-centre trial and randomly assigned811
(1 : 1) to receive either bilateral AAV2-NRTN (180l812
injection volume per hemisphere) into the substan-813
tia nigra (2.0 × 1011 vg/patient, 15L × 2 infusions)814
and putamen (1.0 × 1012 vg/patient, 50L × 3 infu-815
sions), or sham surgery. Again, no statistically816
significant clinical differences were seen in UPDRS817
Part III motor OFF scores at 15-months (primary818
endpoint) between the active treatment and sham819
operated arms.820
Following the NRTN studies, an open-label, dose-821
escalation Phase 1 study of AAV2-GDNF was822
initiated in 2013 (NCT01621581) [49]. In this GDNF823
gene therapy study, 13 (of an intended 24) partici-824
pants with advanced PD received bilateral magnetic825
resonance imaging (MRI)-guided, CED intraputam-826
inal infusions of AAV2-GDNF (9 × 1010 (n = 6),827
3 × 1011 (n = 6), 9 × 1011 vg (n = 1); delivered in828
a 450L volume per putamen. Safety and tolera-829
bility of AAV2-GDNF intraputaminal delivery by830
CED was confirmed by real-time MRI and postop-831
erative monitoring, with no serious adverse events832
(SAEs) attributed either to the procedure, or to the833
investigational product. Increased PET uptake values834
of 18F-DOPA were noted at the documented infu-835
sion sites at the 6-month time point as compared836
to baseline values, with further enhanced uptake837
observed at 18-months post-treatment time point.838
A trend was noted for earlier and more marked 839
increases in patients with shorter disease duration. 840
No significant differences were seen at 18-months 841
between the three treated cohorts in terms of their 842
UPDRS Part III motor scores or total levodopa equiv- 843
alent doses. The unchanged PD motor scores and 844
stabilisation of their anti-parkinsonian medications 845
following putaminal AAV2-GDNF delivery might 846
support possible biological effects of this therapy 847
in participants with advanced PD but this remains 848
unproven. 849
Several key changes were made as part of the 850
AAV2-GDNF Phase 1 study design compared to prior 851
direct infusion studies in PD conducted in the early 852
2000s, including: 853
a) the use of intraoperative MRI-guidance, and 854
gadolinium co-infusion with AAV-GDNF 855
b) using a reflux-resistant delivery cannula with a 856
stepped design to increase distribution within 857
the target putamen while reducing off-target 858
leakage; 859
c) allowing the visualisation and monitoring of 860
CED infusions in real-time with an ability to 861
surgically modify the cannula position and infu- 862
sion parameters to maximise the putaminal 863
coverage, and 864
d) increasing the infusion volumes up to 450L 865
per putamen, 3 times greater than the volume 866
delivered in the Phase II AAV2-NRTN study 867
[46, 48]. 868
Despite these key modifications in methods, the 869
average putaminal volumetric coverage documented 870
by retrospective interim analysis of MRIs was only 871
26%, much lower than that anticipated to be required 872
for a meaningful clinical benefit. In part, this limita- 873
tion in putaminal coverage may have been due to the 874
transfrontal surgical approach to the putamen, where 875
the trajectories are perpendicular to the long axis of 876
the target volume. This inability to broadly cover 877
the putamen with this standard surgical approach 878
may have also been a relevant disadvantage in the 879
AAV2-NRTN and earlier recombinant GDNF protein 880
infusion studies, where there was minimal putaminal 881
transgene expression or effects with small localised 882
changes relative to the radiographic improvement dis- 883
played via18F-DOPA PET imaging. 884
Although long term follow-up for the Phase 1 885
adeno associated virus (AAV) 2-GDNF cohorts is 886
ongoing, enrolment was closed following the interim 887
analysis, due to the insufficient putaminal coverage 888
(mean of 26%).Other studies of a AAV2-L-aromatic 889
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Fig. 1. Transfrontal versus Posterior (occipital) trajectories utilizing CED. MRI-guided stereotactic approaches for vector delivery to the
putamen utilizing convection enhanced delivery (CED) and stepped cannulae. This approach allows for precise targeting, shape-fitting
infusions, and larger delivery volumes to improve the extent of transduced putaminal tissue, thereby increasing transgene production
capacity. With the transfrontal approach, the cannulae are oriented to the short axis of the putamen limiting vector coverage to <30%, often
requiring 2-3 tracts. The posterior (occipital) approach maximizes the delivery by paralleling the putaminal long-axis, requiring only 1 tract,
which achieves >50% putaminal vector coverage with larger infusion volumes.
amino acid decarboxylase (AADC)gene therapy for890
PD [50], however have shown that delivering vol-891
umes up to 1800L per putamen using a CED892
approach is feasible with a good safety profile and893
providing putaminal volumetric coverage of >50%.894
More importantly, this AAV2-AADC PD gene ther-895
apy investigation has provided convincing evidence896
that the clinical benefit improved concurrently with897
increases in volume of vector delivered and thereby898
the extent of putaminal coverage. These findings899
underscore the importance of optimising the trans-900
duced tissue volume and putaminal infusion coverage901
as factors correlating directly with clinical efficacy in902
PD [49].903
These latter efforts have prompted the design of904
a new Phase 1b trial to assess a higher dose of the905
AAV2-GDNF therapeutic in moderately advanced906
PD patients, (similar to those in Phase 1), as well as in907
subjects with early disease (namely within 5 years of908
PD onset). Furthermore, this new study will be using909
a posterior (occipital) trajectory to each putamen,910
(paralleling the long axis), that allows shape-fitting911
CED of higher infusion volumes, thereby improv-912
ing putaminal coverage and GDNF production levels913
more uniformly throughout the putamen [51].This914
posterior putaminal approach is similar to that915
recently reported in the GDNF protein infusion study916
[38] and has also been safely performed using MRI- 917
guidance and CED, in the ongoing AAV2-AADC 918
study (NCT03562494) (see Fig. 1). 919
WHERE NEXT? 920
The question as to whether GDNF has a compet- 921
itive future in the treatment of PD is still unclear. A 922
number of conclusions can be drawn from the stud- 923
ies undertaken to date with GDNF and related factors 924
(see Table 1) along with a number of recommenda- 925
tions about what another trial with GDNF should 926
consider and thus might look like (see Table 2). 927
Table 1
Summary of main findings on the effects of GDNF and related
factors in models and clinical trials in PD
• Studies have shown a statistically significant response in some
patients, but these are not consistent, and the majority of studies
have been negative in terms of reaching their primary outcome;
• Striatal dopamine has increased in most patients in receipt of
GDNF as evidenced using 18F –dopa PET imaging;
• There is little evidence of sufficient retrograde transport of
GDNF/NRTN to the substantianigra in patients when the agent
is delivered into the striatum;
• Postmortem studies show that where there is expression of
GDNF/NRTN there is some upregulation of TH.
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Table 2
Factors to consider in future clinical trials with GDNF and related factors in PD
What form should the GDNF be given in?
• A gene therapy approach was favoured over protein infusions given the complexity of the neurosurgical intervention required for the
former and the burden this places on the patients with Parkinson’s disease.
• Consider using mammalian cell produced GDNF and NRTN proteins.
Patient type
• Younger patients with marked L-dopa response and no major ventral striatal dopamine loss on dopamine imaging.
• Avoid certain genetic forms/variants associated with Parkinsonism (Parkin; GBA).
Disease stage
• Avoid late stage disease.
Dose given
• Depends on the neurotrophic factor that is being delivered, but probably need higher doses than have been trialed to date (with the
exception of the first ICV trial of GDNF).
Volume given
• Depends on delivery system but need to give up to ∼1 ml per striatum treated.
Delivery device
• Several now in existence, e.g., Renishaw, Clear point.
Need for adjunct therapies
• Not proven to be needed, although preclinical data suggests that Nurr 1 agonists may enhance the efficacy of GDNF—so perhaps this
should be included as part of further trials.
Need for imaging? If so with what?
• F-dopa PET imaging seems to have provided useful information in trials to date, but need for other PET markers looking DA
turnover/release as well as network reconstruction.
Trial end points: What and when?
• Standard measures UPDRS part 2 ± PDCore scores at 18–24 month as the primary end point.
• Sample size currently undecided given lack of major effects seen to date which would allow one to power such a study.
Trial design
• Consider a delayed start design to the trial or arandomized double-blind placebo-controlled study.
• Keep the trial outcomes and measures simple.
• In postmortem samples, it is important to show that GDNF and NRTN have activated RET-dependent signalling pathways or to show
direct RET receptor activation.
Health economics for this agent?
• Depends on where it is positioned
BUTalthough it works uniquely to restore the dopaminergic nigrostriatal, it will nevertheless have to compete with other “DA”
therapies/interventions- new dopamine drugs; DuoDopa®; Deep Brain Stimulation etc and the newer dopamine gene or cell-based
therapies should they be shown to work.
• Currently it would not be competitive given the size of effects seen to date, but this may relate to suboptimal delivery, etc.
In particular, it was felt that a viral delivery sys-928
tem using some of the newer modified approaches929
would be advantageous given the one-off nature of930
the surgery compared to the relative complexity of the931
neurosurgery needed to implant the infusion delivery932
systems used in the recent GDNF trial and conse-933
quent requirement for on-going infusions. That said,934
the efficacy of GDNF may require intermittent rather935
than continuous RET receptor stimulation and, whilst936
in the development phase, understanding the exact937
dose administered and retaining the ability to reduce938
and stop dosing may have utility. In addition, it939
seems logical to assume that the individuals most940
likely to benefit from such a treatment would be941
those individuals with most neurons and fibres left942
to rescue, namely patients with early stage PDwith 943
evidence of fibre loss restricted to the dorsal striatum 944
[52]—where the therapeutic agent would be targeted. 945
If such an approach were recommended, then ensur- 946
ing the patient actually has Dopa-responsive PD will 947
be critical, and the use of imaging to help support 948
such a diagnosis would be essential, including both 949
DA imaging as well possibly fluorodeoxyglucose 950
(FDG) PET (for both diagnostic stratification and cor- 951
roboration of functional target engagement) [53]. In 952
addition, the exclusion of certain genetic forms of 953
parkinsonism may be wise, for example GBA het- 954
erozygote patients, given that they progress more 955
quickly especially with pathology outside of the DA 956
nigrostriatal pathway [54, 55]. 957
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Whether an adjunct therapy to up regulate Nurr1958
would be required is still unclear given the clinical959
data to date, but the preclinical data would suggest960
this. However, there is no such agent that has yet961
been identified with a safety profile that is accept-962
able and even if one existed, questions still arise as963
to how long such a therapy should be given. Coupled964
to this is a need to better understand the optimal dose965
of GDNF and volume of its distribution, to ensure966
that the treatment has the best chance of showing a967
clinical effect, and that this effect is the maximal one968
that one could expect for that agent. Finally, since969
E. coli cannot form seven disulphide bonds correctly970
and glycosylate GDNF, the use of mammalian cells971
to make GDNF should be considered if protein infu-972
sions are being considered although this brings with973
it major cost implications.974
As to what any trial should look like, there is still975
much debate as to what primary end-point should be976
used and at what time point, and input from the patient977
community on this will be vital going forward. How-978
ever, this end point should reflect changes in those979
clinical aspects of PD that respond to dopaminergic980
interventions given this is the pathway being targeted981
by these treatments. A double-blind sham surgery982
trial would be the preferred design for future studies,983
although whether more optimisation of the delivery984
of GDNF should be carried out before such a trial is985
undertaken is debatable. Overall there was a consen-986
sus from the workshop, that longer trials may be better987
for fully exploring whether this agent can mediate988
neurorestoration and thus waiting at least 18 months989
from the start of any therapeutic intervention would990
increase the chances of seeing any such effects. In991
addition, using composite end points may also have992
some merit given thatthe use of any single one, such993
as the UPDRS part III score, has limitations. As to994
what that composite clinical end point should look995
like is unclear as regulatory agencies are currently996
not accepting these for licensing purposes. However,997
one that has recently been proposed relating to the998
recent Bristol GDNF trial, PDCORE, embraces good999
quality on-time; activities of daily living and reflects1000
previous participant feedback [56].1001
In addition to the use of wild type GDNF and1002
NRTN given as protein deliveries ora gene ther-1003
apy, other similar approaches for treating PD were1004
also discussed. In pre-clinical studies, new GDNF1005
and NRTN mutants with improved diffusion and1006
stability have shown beneficial effects [57, 58]. Fur-1007
thermore, to overcome the limitations of some of1008
the pharmacokinetic properties of the GDNF and1009
NRTN proteins, a blood-brain-barrier penetrating 1010
small molecule GDNF receptor agonist has recently 1011
been developed. This compound activates RET- 1012
dependent intracellular signaling cascades in DA 1013
neurons both in vitro and in vivo and also stimulates 1014
the release of dopamine in the mouse striatum—all of 1015
which suggests that this agent could be a novel future 1016
treatment of PD [59]. 1017
In this respect, cerebral dopamine neurotrophic 1018
factor (CDNF) is a relatively recently discov- 1019
ered endoplasmic reticulum (ER) located, but also 1020
secreted, protein that protects and restores the func- 1021
tion of DA neurons in rodent and non-human primate 1022
models of PD and does so more effectively than 1023
GDNF [60]. CDNF is very different from other 1024
known trophic factors–it has a unique structure 1025
and mode of action protecting neurons by inhibit- 1026
ing cell death, regulating ER stress, the unfolded 1027
protein response (UPR) and reducing inflammation 1028
[61]. In addition, CDNF rescues only ER-stressed or 1029
degenerating neurons and does not influence naı¨ve 1030
healthy neurons. This agent is now the subject on 1031
an EUH2020 funded phase I–II clinical trial in PD 1032
patients (NCT03295786) [61]. 1033
CONCLUSIONS 1034
This special workshop comprehensively covered 1035
the studies evaluating GDNF and the related trophic 1036
factor NRTN in PD both preclinically and clinically. 1037
It critically appraised the work so that conclusions 1038
could be drawn as towhat has been shown andwhat 1039
has not been shown with these agents. It was gen- 1040
erally agreed that GDNF and NRTN have worked 1041
relatively well in neurotoxic animal models of PD 1042
but that their translation to the clinic has so far failed 1043
to show a major impact—perhaps highlighting the 1044
predictive limitations of toxin animal models being 1045
commonly used in the preclinical space in PD and the 1046
way we plan clinical trials. 1047
Clinically, there is evidence that these neurotrophic 1048
factors are able to rescue the expression of THin the 1049
human PD brain with some suggestion of a clinical 1050
correlate. Nevertheless, the current size of any such 1051
effect is not competitive compared to what is already 1052
clinically available for the DA-related features of PD 1053
(DuoDopa®; deep brain stimulation; lesion surgery 1054
such as pallidotomy; apomorphine pumps, etc.) and 1055
this may also be the case with new agents that are cur- 1056
rently being trialled in PD around dopamine rescue 1057
(stem cell derived DA neurons; CDNF, “dopamine” 1058
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gene therapies). However, it must be realised that1059
these agents are uniquely designed to restore and1060
regenerate the dopaminergic pathway which is very1061
different from these other symptomatic therapies.1062
In conclusion, further work is needed to under-1063
stand better what can be achieved with GDNF and1064
related factors in the clinic to improve the lives of1065
patients with PD, although ultimately whether it will1066
ever have a competitive place for treating people with1067
PD remains unclear.1068
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